US 12,459,899 B2
Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
Eunhee Kim, Daejeon (KR); Changmin Park, Gyeonggi-do (KR); Sehwan Oh, Gyeonggi-do (KR); Younghoon Kim, Gyeonggi-do (KR); Juhee Lee, Gyeonggi-do (KR); Jaehee Seol, Gyeonggi-do (KR); Ahram Shim, Gyeonggi-do (KR); Younggwan Kim, Gyeonggi-do (KR); Tae-Sung Koo, Gyeonggi-do (KR); and Ki-Hong Jang, Daejeon (KR)
Assigned to DIGMBIO, INC., Gyeonggi-do (KR)
Appl. No. 17/771,773
Filed by DIGMBIO. INC., Gyeonggi-do (KR)
PCT Filed Oct. 29, 2020, PCT No. PCT/KR2020/014947
§ 371(c)(1), (2) Date Apr. 25, 2022,
PCT Pub. No. WO2021/086077, PCT Pub. Date May 6, 2021.
Claims priority of application No. 10-2019-0136798 (KR), filed on Oct. 30, 2019.
Prior Publication US 2023/0027362 A1, Jan. 26, 2023
Int. Cl. C07D 217/24 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A61P 27/02 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 451/02 (2006.01)
CPC C07D 217/24 (2013.01) [A23L 33/10 (2016.08); A23L 33/40 (2016.08); A61P 27/02 (2018.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01); C07D 451/02 (2013.01); A23V 2002/00 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A compound represented by Chemical Formula 1 below, a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
In Chemical Formula 1 above,

OG Complex Work Unit Chemistry
is

OG Complex Work Unit Chemistry
R1 is methyl, and n is 0 or 1,
L1 is C1-3 alkylene unsubstituted or substituted with oxo;
Y is a 4- to 8-membered monocyclic or polycyclic heterocycloalkylene or heterocycloalkenylene containing one or more heteroatom selected from the group consisting of N, O, and S;
L2 is a single bond, —NHCO—, —NR2—, —O—, or straight or branched C1-10 alkylene substituted with one or more substituents selected from the group consisting of oxo and amino, R2 is hydrogen or C1-6 alkyl; and
Z is C3-8 cycloalkyl, 5- to 8-membered heterocycloalkyl containing one or more heteroatom selected from the group consisting of N, O, and S, phenyl, or 5- to 8-membered heteroaryl containing one or more heteroatom selected from the group consisting of N, O, and S, wherein the cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl may be each independently unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, straight or branched C1-6 alkyl unsubstituted or substituted with one or more halogen, straight or branched C1-6 alkoxy unsubstituted or substituted with one or more halogen, —CO2H, C1-6 alkoxycarbonyl, and C1-6 alkylcarbonylamino.